Boglarka Gyurkocza

Boglarka Gyurkocza

Auto-generated profile, based on publicly available information

Boglarka Gyurkocza

Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2014 in Blood
Verified
Journal Article
Open access
PDF file
BGBoglarka Gyurkocza
Boglarka Gyurkocza
BSBrenda Marie Sandmaier
Brenda Marie Sandmaier
An essential component of allogeneic and autologous hematopoietic cell transplantation (HCT) is the conditioning regimen administered before the hematopoietic cell infusion. Early regimens relied on dose intensity, assuming that high-dose chemoradiotherapy would eliminate malignant disease and reinfusion of the graft would then restore hematopoiesis. However, as the contribution of graft-versus-tumor effects to the success of allogeneic HCT was recognized over time, in an effort to exploit these, many investigators lowered the dose of radiation and chemotherapeutic agents in the preparative regimen. This resulted in a major paradigm shift, and consequently, the pool of eligible patients underwent a remarkable expansion. In this article, we provide a review of the definition of high-dose, reduced-intensity, and nonmyeloablative conditioning regimens, the most commonly used agents and combinations, and the evolution of some early regimens. We also provide a brief review of the toxicities associated with these regimens.

26 September 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
YTYing Taur
Ying Taur
KCKatharine Coyte
Katharine Coyte
JSJonas Schluter
Jonas Schluter
ERElizabeth Robilotti
Elizabeth Robilotti
CFCesar Figueroa
Cesar Figueroa
JXJoao B. Xavier
Joao B. Xavier
A randomized clinical trial demonstrates that autologous fecal microbiota transplant can reconstitute the gut microbiota of patients undergoing intensive antibiotic treatment.

5 September 2013 in Blood
Verified
Journal Article
Open access
PDF file
Roland Bruno WalterRoland Bruno Walter
Roland Bruno Walter
SBSarah A. Buckley
Sarah A. Buckley
JPJohn M. Pagel
John M. Pagel
BWBrent L. Wood
Brent L. Wood
BSBarry E. Storer
Barry E. Storer
FAFrederick R. Appelbaum
Frederick R. Appelbaum
Key Points: The negative impact of pre-HCT flow cytometrically determined MRD is similar for AML in CR1 and CR2. Even minute levels of MRD (≤0.1%) are associated with adverse outcome.

3 June 2014 in Leukemia
Verified
Journal Article
Open access
PDF file
Roland Bruno WalterRoland Bruno Walter
Roland Bruno Walter
BGB Gyurkocza
B Gyurkocza
BSB E Storer
B E Storer
CGC D Godwin
C D Godwin
JPJ M Pagel
J M Pagel
BSB M Sandmaier
B M Sandmaier
Minimal residual disease (MRD) is associated with adverse outcome in acute myeloid leukemia (AML) after myeloablative (MA) hematopoietic cell transplantation (HCT). We compared this association with that seen after nonmyeloablative (NMA) conditioning in 241 adults receiving NMA (n=86) or MA (n=155) HCT for AML in first remission with pre-HCT bone marrow aspirates assessed by flow cytometry. NMA patients were older and had more comorbidities and secondary leukemias. Three-year relapse estimates were 28% and 57% for MRDneg and MRDpos NMA patients, and 22% and 63% for MA patients. Three-year overall survival (OS) estimates were 48% and 41% for MRDneg and MRDpos NMA patients and 76% and 25% for MA patients. This similar OS after NMA conditioning was largely accounted for by higher non-relapse mortality (NRM) in MRDneg (30%) compared with MRDpos (10%) patients, whereas the reverse was found for MRDneg (7%) and MRDpos (23%) MA patients. A statistically significant difference between MA and NMA patients in the association of MRD with OS (P<0.001) and NRM (P=0.002) but not relapse (P=0.17) was confirmed. After adjustment, the risk of relapse was 4.51 times (P<0.001) higher for MRDpos patients. These data indicate that the negative impact of MRD on relapse risk is similar after NMA and MA conditioning.

20 April 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RSRainer Storb
Rainer Storb
BGBoglarka Gyurkocza
Boglarka Gyurkocza
BSBarry E. Storer
Barry E. Storer
MSMohamed L. Sorror
Mohamed L. Sorror
KBKarl Blume
Karl Blume
BSBrenda M. Sandmaier
Brenda M. Sandmaier
Purpose: We designed a minimal-intensity conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) in patients with advanced hematologic malignancies unable to tolerate high-intensity regimens because of age, serious comorbidities, or previous high-dose HCT. The regimen allows the purest assessment of graft-versus-tumor (GVT) effects apart from conditioning and graft-versus-host disease (GVHD) not augmented by regimen-related toxicities. Patients and Methods: Patients received low-dose total-body irradiation ± fludarabine before HCT from HLA-matched related (n = 611) or unrelated (n = 481) donors, followed by mycophenolate mofetil and a calcineurin inhibitor to aid engraftment and control GVHD. Median patient age was 56 years (range, 7 to 75 years). Forty-five percent of patients had comorbidity scores of ≥ 3. Median follow-up time was 5 years (range, 0.6 to 12.7 years). Results: Depending on disease risk, comorbidities, and GVHD, lasting remissions were seen in 45% to 75% of patients, and 5-year survival ranged from 25% to 60%. At 5 years, the nonrelapse mortality (NRM) rate was 24%, and the relapse mortality rate was 34.5%. Most NRM was a result of GVHD. The most significant factors associated with GVHD-associated NRM were serious comorbidities and grafts from unrelated donors. Most relapses occurred early while the immune system was compromised. GVT effects were comparable after unrelated and related grafts. Chronic GVHD, but not acute GVHD, further increased GVT effects. The potential benefit associated with chronic GVHD was outweighed by increased NRM. Conclusion: Allogeneic HCT relying on GVT effects is feasible and results in cures of an appreciable number of malignancies. Improved results could come from methods that control progression of malignancy early after HCT and effectively prevent GVHD.

10 June 2010 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BGBoglarka Gyurkocza
Boglarka Gyurkocza
RSRainer Storb
Rainer Storb
BSBarry E. Storer
Barry E. Storer
TCThomas R. Chauncey
Thomas R. Chauncey
TLThoralf Lange
Thoralf Lange
BSBrenda Marie Sandmaier
Brenda Marie Sandmaier
Purpose: Allogeneic hematopoietic cell transplantation (HCT) after high-dose conditioning regimens imposes prohibitively high risks of morbidity and mortality for patients with high-risk acute myeloid leukemia (AML) who are older or have comorbid conditions. Here, we examined outcomes after nonmyeloablative allogeneic HCT in such patients. Patients and Methods: Two hundred seventy-four patients (median age, 60 years) with de novo or secondary AML underwent allogeneic HCT from related (n = 118) or unrelated donors (n = 156) after conditioning with 2 Gy of total-body irradiation (TBI) with or without fludarabine. A calcineurin inhibitor and mycophenolate mofetil were used for postgrafting immunosuppression. Results: With a median follow-up of 38 months in surviving patients, the estimated overall survival at 5 years was 33%. The estimated 5-year relapse/progression and nonrelapse mortality rates were 42% and 26%, respectively. The cumulative incidences of grades 2, 3, and 4 acute graft-versus-host disease (GVHD) were 38%, 9%, and 5%, respectively. The cumulative incidence of chronic GVHD at 5 years was 44%. Patients in first and second complete remission had better survival rates than patients with more advanced disease (37% and 34% v 18%, respectively). Patients with HLA-matched related or unrelated donors had similar survivals. Unfavorable cytogenetic risk status was associated with increased relapse and subsequent mortality. Chronic GVHD was associated with lower relapse risk. Conclusion: Allogeneic HCT from related or unrelated donors after conditioning with low-dose TBI and fludarabine, relying almost exclusively on graft-versus-leukemia effects, can result in long-term remissions in older or medically infirm patients with AML.